SEMA3F and breast cancer: Our data provide clear evidence that SEMA3F and its receptors NRP1 and NRP2, which were previously used in the prognosis of invasive BC subtypes, also participate in fostering DCIS to IDC progression through the induction of an EMT process in cancer cells and consequently enhancing migration and invasion.